Financial Data and Key Metrics Changes - For Q4 2025, revenue was $194.8 million, with Adjusted EBITDA at $65 million, leading to a full year revenue of $796.9 million, a 1% increase year-over-year [20] - Full year Adjusted EBITDA was $270.5 million, reflecting a 4% growth over 2024 [20] - Prescription transactions revenue declined by 6% year-over-year to $544 million, impacted by the Rite Aid bankruptcy and lower volume through an Integrated Savings Program partner [21] - Subscription revenue decreased by 3% year-over-year to $83.8 million, although early adoption of condition-specific subscriptions showed promise [21] - Revenue from Pharma Direct increased to $151.4 million, up 41% year-over-year, driven by deeper sell-through at manufacturers [21] Business Line Data and Key Metrics Changes - Pharma Manufacturer Solutions, now referred to as Pharma Direct, has become a key growth engine, with full year revenue up more than 40% in 2025 [9][21] - The prescription marketplace showed progress with order volume up 83% quarter-over-quarter, and direct contracts established with 9 of the top 10 retail pharmacies [15] - Condition-specific subscriptions, particularly for weight loss, have exceeded expectations, indicating strong potential for future revenue growth [16][21] Market Data and Key Metrics Changes - The healthcare landscape is shifting towards affordability and transparency, with consumers increasingly expecting direct-to-consumer access [7][10] - The growth of GLP-1 treatments for weight management has accelerated direct-to-consumer models, highlighting the need for transparent pricing and convenience [10][12] Company Strategy and Development Direction - The company is evolving its business model to focus on Pharma Manufacturer Solutions as a key growth driver, reflecting changes in prescription access and pharmacy economics [8][9] - GoodRx aims to enhance its core platform by accelerating subscriptions and deepening retail relationships, positioning itself for long-term growth despite near-term financial impacts [9][23] - The introduction of Employer Direct is seen as a natural extension of the GoodRx platform, addressing gaps in traditional insurance coverage [18][19] Management's Comments on Operating Environment and Future Outlook - Management noted that affordability pressures and policy dynamics are reshaping access and pricing in healthcare, which plays to GoodRx's strengths [7][25] - The company anticipates pressure on prescription transactions revenue in 2026 but expects Pharma Direct revenue to grow at least 30% year-over-year [23][24] - Management expressed confidence in the strategic direction and the ability to deliver value in a changing healthcare environment [25][26] Other Important Information - The company ended the year with $261.8 million in cash and approximately $80 million in unused capacity under its revolving credit facility [22] - Share repurchases totaled approximately 48.9 million shares at an average price of $4.45 per share, signaling management's confidence in the company's future [22] Q&A Session Summary Question: Can you elaborate on the revenue guidance and unit economics? - Management explained that the decline in prescription transaction revenue is due to the impact of Rite Aid's bankruptcy and a shift of claims to Pharma Direct, which is expected to stabilize over the long term [30][32] Question: How is the pharma budget spending environment affecting Pharma Direct programs? - Management noted that spending has been pulled forward this year, with pharmaceutical manufacturers continuing to invest in direct-to-consumer programs [42][44] Question: What is the future of the legacy business amidst the focus on Pharma Direct? - Management confirmed that the core Rx Marketplace will remain foundational, but there is a strategic shift towards direct-to-consumer experiences and partnerships with pharmaceutical manufacturers [51][52] Question: How is the company addressing margin pressure and price stability? - Management acknowledged that while there is margin pressure, the interrelation between Pharma Direct and the core business allows for shared brand economics, which is expected to stabilize pricing in the medium term [93]